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Abstract Translation elongation consumes a high proportion
of cellular energy and can be regulated by phosphorylation of
elongation factor eEF2 which inhibits its activity. We have
studied the e¡ects of ATP depletion on the phosphorylation of
eEF2 in adult rat ventricular cardiomyocytes. Energy depletion
rapidly leads to inhibition of protein synthesis and increased
phosphorylation of eEF2. Stimulation of the AMP-activated
protein kinase also causes increases eEF2 phosphorylation.
Only at later times is an e¡ect on mTOR signalling observed.
These data suggest that energy depletion leads to inhibition of
protein synthesis through phosphorylation of eEF2 independent-
ly of inhibition of mTOR signalling.
% 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Protein synthesis consumes a high proportion of cellular
energy (typically 25^30% [1]). In particular, the elongation
process consumes at least four high-energy phosphodiester
bonds for each amino acid residue added to the growing
chain. Cells have devised mechanisms to match the availabil-
ity of metabolic energy to the demand for energy by anabolic
processes and its availability, e.g. from fuel oxidation. One
important example of this is the 5PAMP-activated protein ki-
nase (AMPK) which is activated when the cellular energy
charge falls due to a rise in the AMP/ATP ratio [2]. AMPK
is known to phosphorylate a number of enzymes and other
proteins to shut o¡ energy-requiring processes and favour
those that can generate metabolic energy. It has also been
suggested that reduced cellular ATP levels decrease the activ-
ity of the protein mTOR (mammalian target of rapamycin;
mTOR activity is inhibited by rapamycin; [3]), which lies up-
stream of, and regulates, several proteins involved in mRNA
translation.
These targets for mTOR signalling include the kinases that
phosphorylate ribosomal S6 [4]. Two S6 kinase genes exist in
mammals, the product of the S6K1 gene being better under-
stood than S6K2. Rapamycin blocks the activation of the S6
kinases, indicating an essential role for mTOR in their regu-
lation. mTOR is also required for regulation of the eukaryotic
initiation factor (eIF) 4E-binding protein, 4E-BP1, which in
its hypophosphorylated state binds to and inhibits eIF4E.
eIF4E interacts with the 5P-cap of the mRNA (which contains
7-methylGTP) and also binds the sca¡old protein eIF4G,
thereby recruiting other factors and the 40S ribosomal subunit
to the mRNA [5]. Insulin induces the phosphorylation of 4E-
BP1 and its release from eIF4E to facilitate cap-dependent
translation [5,6].
The translation elongation process is regulated through the
phosphorylation of eukaryotic elongation factor (eEF) 2.
Phosphorylation at Thr56 inactivates eukaryotic elongation
factor 2 (eEF2) and is catalysed by a very speci¢c and unusual
protein kinase, eEF2 kinase [7,8] (formerly termed Ca2þ/cal-
modulin kinase III [9,10]). Insulin elicits dephosphorylation of
eEF2 by inactivating eEF2 kinase [11,12], and this involves
phosphorylation of eEF2 kinase by S6K1 at Ser365 (rat se-
quence [13]). Inactivation of eEF2 kinase and the dephosphor-
ylation of eEF2 in response to insulin are sensitive to rapa-
mycin, re£ecting this input from S6K1 [11].
Heart muscle cells have a high and varying requirement
for metabolic energy, the demand increasing as contraction
is stimulated. We have previously shown that L-adrenergic
stimulation, which exerts positive inotropic and chrono-
tropic e¡ects on contraction, causes activation of eEF2 ki-
nase and phosphorylation of eEF2 in isolated adult rat car-
diomyocytes (ARVC [14]). This presumably serves to reduce
the rate of protein synthesis to divert energy to support
contraction. Heart muscle is a highly oxidative tissue with
much of its energy being generated by mitochondrial oxida-
tion of pyruvate or fatty acids. Cardiac energy supply is
thus greatly impaired by interruption of the supply of oxy-
gen (such as occurs in cardiac ischaemia or anoxia). This
e¡ect can be mimicked in vitro by inhibiting mitochondrial
function. Here we have explored the e¡ects of such manip-
ulations on phosphorylation of eEF2 and on targets of the
mTOR pathway. Our data show that increased phosphory-
lation of eEF2 is an immediate e¡ect of disturbing energy
metabolism in this way, and that impairment of mTOR
signalling only occurs later and/or under more severe con-
ditions. Our data also imply a role for AMPK in regulating
the phosphorylation of eEF2 under conditions of ATP de-
pletion.
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2. Materials and methods
2.1. Materials
The mitochondrial uncoupler carbonyl cyanide m-chlorophenylhy-
drazone (CCCP) and the ATP-synthesis inhibitor oligomycin were
from Sigma Chemical, Poole Dorset, UK; 5-aminoimidazole-4-car-
boxyamide 1-L-D-ribofuranoside (AICAR) was from Toronto Re-
search Chemicals, ON, Canada. Rats were from Charles River (Mar-
gate, Kent, UK). The antisera for eEF2, eEF2 phosphorylated at
Thr56, 4E-BP1, eIF4E, eIF4G and S6K1, have been described previ-
ously [14^19]. The antibody that recognises acetyl-CoA carboxylase
when phosphorylated at Ser79 was a kind gift from Professor Gra-
hame Hardie, Dundee (see [20]). [35S]Methionine was from Amersham
Biosciences (Little Chalfont, Bucks, UK).
2.2. Isolation, culture and treatment of adult rat ventricular myocytes
Adult rat ventricular cardiomyocytes were isolated and maintained
exactly as described earlier [12]. Where indicated, cells were treated
with insulin (10 nM, 20 min) prior to the addition of further stimuli.
Extracts were prepared as described earlier using our standard lysis
bu¡er, which contains a cocktail of protease and phosphatase inhib-
itors [12]. Protein concentrations were determined by Bradford’s
method [21].
2.3. Gel electrophoresis and western blotting
Gel electrophoresis was performed as described earlier [12], using
running gels with the indicated percentage of acrylamide: for S6K1,
10%; for 4E-BP1, for 12.5%; for eEF2, 10%; for ACC, 8%. Transfer
was by the ‘wet’ method. In all cases, Immobilon0 membrane was
used. Blots were visualised by enhanced chemiluminescence (ECL).
For analysis of the binding of eIF4G and 4E-BP1 to eIF4E, proteins
were subjected to a⁄nity chromatography on m7GTP-Sepharose as
described in [17].
2.4. Other procedures
Protein synthesis was assayed exactly as described earlier [14]. For
determination of adenine nucleotides, overnight cultures of ARVC
were extracted in ice-cold 7% perchloric acid and centrifuged at
10 000Ug for 10 min at 4‡C. The protein pellet was resuspended in
1 M NaOH and the protein content determined by Bradford’s assay
[21]. The supernatant was neutralised with 3 M KHCO3 to approx-
imately pH 5. The potassium perchlorate was centrifuged out and the
supernatant was frozen in liquid nitrogen. Samples were analysed in
duplicate by HPLC, using a Supelcosil LC-18-T column (3-WM pore
size) and an isocratic gradient of 0.1 M KH2PO4/4 mM tetrabutylam-
monium hydrogen sulphate (phase A) and phase A:MeOH (70:30,
phase B). These analyses were kindly performed by Dr Steve Land,
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Fig. 1. ATP depletion or AICAR treatment increases phosphorylation of eEF2. A: ARVC were treated with insulin (see Materials and meth-
ods) and then with the indicated agent (AICAR, 1 mM; CCCP, 10 WM; oligomycin, 1 WM) for the times shown. Cells were then lysed and
equal amounts of cell protein (usually 30 Wg) were analysed by SDS^PAGE (10% gel), followed by Western blotting with an antibody that rec-
ognises eEF2 only when phosphorylated at Thr56 (upper part) or, as loading control, one that binds eEF2 irrespective of its state of phosphor-
ylation. 3, no treatment other than insulin. B: As A, but cells were not preincubated with insulin and were only treated with CCCP. Control
blots con¢rmed equal loading (not shown). C: As A, but some dishes were not treated with insulin (3), while others were (+), prior to addi-
tion of the agents shown (concentrations as above). Equal loading was con¢rmed by a parallel blot using the anti-eEF2 antibody mentioned in
A, but this control is only shown for AICAR-treated cells. D: As A, except cells were treated with AICAR or CCCP for the times shown, and
the blot was probed with an antibody that recognises ACC when it is phosphorylated at Ser79. Similar data were obtained in four (D) or ¢ve
(other panels) separate experiments.
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Tayside Institute of Child Health, Ninewells Hospital, Dundee, as
described in [20].
3. Results and discussion
3.1. ATP depletion rapidly leads to inhibition of protein
synthesis and phosphorylation of eEF2
Treatment of ARVC with the uncoupler CCCP resulted in
a very marked inhibition of protein synthesis within 2 min
(Table 1; it is not possible to study protein synthesis over
shorter time intervals). Oligomycin treatment also markedly
inhibited protein synthesis (Table 1).
Given the substantial inhibition of protein synthesis seen
here, it was important to examine whether CCCP treatment
a¡ected the phosphorylation of proteins that are known to
regulate overall protein synthesis rates. We analysed eEF2
and eIF2K because phosphorylation of either can cause a
general inhibition of mRNA translation [7,22]. As shown in
Fig. 1A, CCCP rapidly and markedly increased the phosphor-
ylation of eEF2 at its regulatory site, Thr56. Phosphorylation
was maximal by 1 min after addition of CCCP (Fig. 1B). At
later times, eEF2 phosphorylation fell. We surmise that, at
these later times, cellular ATP levels are so low that phos-
phorylation of eEF2 by eEF2 kinase within the cells is im-
paired.
Treatment of ARVC with oligomycin (which inhibits mito-
chondrial ATP synthesis, rather than dissipating the electro-
chemical gradient across the mitochondrial membrane), also
caused increased phosphorylation of eEF2, although the e¡ect
was slower in onset. Even by 10 or 20 min of treatment, the
level of eEF2 phosphorylation was still lower than that ob-
served after 2 min of treatment with CCCP (Fig. 1A).
Insulin decreases the level of phosphorylation of eEF2 in
ARVC, as con¢rmed here (Fig. 1C) [12]. Following treatment
of ARVC with insulin, CCCP or oligomycin increased the
phosphorylation of eEF2, although not to the levels seen in
the absence of insulin (Fig. 1C). The e¡ects of insulin and
ATP-depleting agents on the phosphorylation of eEF2 there-
fore appear to be exerted through mutually antagonistic
mechanisms.
3.2. AICAR, an activator of AMPK, also causes
phosphorylation of eEF2
Treatment of cells with CCCP (which collapses the electro-
chemical gradient across the mitochondrial membrane) is ex-
pected to have a marked e¡ect on the adenylate energy charge
within the cell. Measurements of the concentrations of ATP,
ADP and AMP revealed that in control cells the energy
charge (de¢ned as ATP+1/2ADP/[total adenine nucleotides],
[23]) was 0.79, in line with earlier ¢ndings for cardiomyocytes
[24] (Table 2). As anticipated, treatment with CCCP rapidly
decreased the ratio, with a substantial change already being
evident by 2 min.
One mechanism by which a fall in the cellular energy charge
(i.e. an increased AMP/ATP ratio) could a¡ect the phosphor-
ylation of eEF2 is through activation of AMPK. Targets for
AMPK include acetyl-CoA carboxylase (ACC), an enzyme
which is important in regulating both anabolic and catabolic
processes. To assess whether the conditions used here led to
activation of AMPK, we examined the phosphorylation of
Ser79 in ACC. Treatment of ARVC with CCCP caused a
marked and rapid rise in the phosphorylation of ACC (Fig.
1D), indicative of a rise in the activity of AMPK by 2 min, a
time at which phosphorylation of eEF2 is maximal (Fig.
1A,B). By 20 min, phosphorylation of ACC had declined.
This is similar to the situation for eEF2 (Fig. 1A,B) and
may arise for similar reasons.
The data above suggested that AMPK might be involved in
regulating the phosphorylation of eEF2 in ARVC. To test
this, we treated ARVC with AICAR, a compound that,
upon intracellular conversion to 5-aminoimidazole-4-carbona-
mide riboside monophosphate (ZMP), yields an activator of
AMPK [2]. It has previously been reported that AICAR is
rather ine¡ective in activating AMPK in heart cells, probably
due to ine⁄cient conversion to ZMP [25]. Nonetheless, we did
see a modest increase in the phosphorylation of eEF2 upon
treatment of our adult cardiomyocytes with AICAR, both in
Table 1
E¡ects of ATP depletion or AICAR on protein synthesis in ARVC
Condition Rate of protein synthesis ([35S]methionine incorporation as % of insulin-treated control) n
AICAR, 1 mM
5 min 69.5T 1.4 6
20 min 66.3T 5.0 7
CCCP, 10 WM
2 min 4.8T 2.9 9
5 min 7.9 T 1.7 8
10 min 11.1T 6.8 9
Oligomycin, 1 WM
5 min 38.8T 6.9 9
20 min 43.0T 2.1 6
ARVC were preincubated with insulin for 20 min and then treated as indicated. [35S]Methionine was added immediately after the time indicated
for a period of 15 min, after which cells were lysed and samples processed for measurements of incorporation of label into protein [14] and
protein concentration [21]. Data are expressed as % of insulin-treated (meanTS.E.M. (n is indicated for each set)) and are normalised for the
protein content of the lysate.
Table 2
Adenylate energy charge of ARVC
Condition Energy charge
Control 0.79T 0.01
AICAR, 5 min 0.79T 0.02
AICAR, 10 min 0.75T 0.02
AICAR, 15 min 0.78T 0.02
CCCP, 2 min 0.15T 0.07
CCCP, 5 min 0.11T 0.03
CCCP, 10 min 0.09T 0.03
ARVC were treated as indicated (CCCP, 10 WM; AICAR, 1 mM)
for the times shown and then acid extracts were prepared and pro-
cessed for measurement of the levels of adenine nucleotides. The
adenylate energy charge is de¢ned as [ATP]+1/2[ADP]/total (ATP
+ADP+AMP). Data are given as meanTS.E.M. (n=4).
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the absence and presence of pretreatment of the cells with
insulin (Fig. 1A,C). As expected, AICAR did not alter the
adenylate charge within the cells (Table 2). It was clear
from the HPLC analysis of the nucleotide levels that treat-
ment of cells with AICAR led to the accumulation of a peak
corresponding to ZMP, which was not observed for cells that
had not been treated with AICAR. Based on the mean of
duplicate determinations (which gave results within 10% of
one another), levels of ZMP were 0.02, 0.09 and 0.22 nmol/
mg protein at times of 5, 10 and 20 min after addition of
AICAR to the cells. These are similar to the concentrations
measured in skeletal muscles of rats injected with AICAR,
and which activated AMPK [26]. Treatment of ARVC with
AICAR also caused an increase in the phosphorylation of
ACC, although not to the extent seen in response to CCCP
(Fig. 1D). These data suggest that, consistent with recent ¢nd-
ings for certain other cell types [27], activation of AMPK
leads to increased phosphorylation of eEF2. The mechanisms
underlying this remain unclear [27], and are currently under
investigation using more tractable cell types than ARVC.
AICAR treatment also inhibits protein synthesis in ARVC
(Table 1), although to a smaller e¡ect than CCCP. This
may re£ect the fact that AICAR increases eEF2 phosphory-
lation to a lesser extent than CCCP (Fig. 1A,C).
Analysis of the phosphorylation of eIF2K failed to reveal
any change in the phosphorylation of this protein in response
to CCCP, oligomycin or AICAR in several separate experi-
ments (data not shown). Thus, inhibition of protein synthesis
caused by mitochondrial poisons correlates with phosphory-
lation of eEF2 (an event known to impair overall protein
synthesis) but is not accompanied by any change in the phos-
phorylation of another regulator of total protein synthesis,
eIF2. This di¡ers from the conclusions of Munoz et al. [28],
who, using a quite di¡erent cell type (PC12 cells), found that
CCCP treatment did cause an increase in the phosphorylation
of eIF2K. This e¡ect was not observed in our study, indicating
that this is not a universal response of mammalian cells to
ATP depletion.
3.3. Only prolonged treatment with CCCP a¡ects targets of
mTOR signalling
Recent work has shown that the activity of eEF2 kinase can
be decreased following its phosphorylation (at Ser365 in the
rat protein) by S6K1 or p90RSK [13]. We therefore considered
the possibility that depletion of ATP might inactivate these
upstream kinases, thereby increasing eEF2 kinase activity and
also eEF2 phosphorylation. In the case of p90RSK, its up-
stream activators, Erk1/2 are essentially inactive either in un-
treated ARVC or after insulin treatment [12]. Consonant with
this, p90RSK is inactive in such cells (L. Wang, unpublished
data) and a role for inactivation of p90RSK can therefore be
rejected. S6K1 does show basal activity in ARVC and its
phosphorylation/activity are increased by insulin [12]. It was
therefore possible that ATP-depletion led to phosphorylation
of eEF2 by causing the dephosphorylation and inactivation of
S6K1. Phosphorylation of S6K1 (which is linked to its acti-
vation) is associated with a retardation of its mobility on
SDS^PAGE. In insulin-treated cells, S6K1 appeared as three
distinct bands on SDS^PAGE, the middle one being the
strongest. Treatment of ARVC with CCCP for 1 min, a
time at which eEF2 phosphorylation is already maximal,
had no e¡ect on the mobility of S6K1 (Fig. 2, compare ¢rst
and last lanes). At later times, a shift to faster migrating, less
phosphorylated forms was apparent. An increase in the inten-
sity of the fastest migrating band (starred in Fig. 2) was ob-
served by 2 min and this became the main species by 10 min.
This indicates inactivation of S6K1. Oligomycin treatment
also resulted in dephosphorylation of S6K1, but the e¡ect
was smaller and slower, with S6K1 migrating in roughly equal
proportions of the middle and fastest species by 20 min.
The data are consistent with the idea proposed by Dennis et
al. [3] that ATP depletion causes inactivation of signalling
through mTOR. However, this change is markedly slower in
onset than the increase in eEF2 phosphorylation (which oc-
curs by 1 min of CCCP treatment, Fig. 1), possibly because
severe or prolonged ATP depletion is required for this e¡ect
(in agreement with the data of [27]). To study this further we
examined a second target of mTOR signalling, the transla-
tional repressor 4E-BP1.
In its hypophosphorylated state, 4E-BP1 binds to and in-
hibits eIF4E. In response to, e.g. insulin, 4E-BP1 undergoes
phosphorylation at multiple sites and is released from eIF4E,
e.g. in ARVC [12]. ARVC were treated with insulin for 20 min
and then with CCCP for di¡erent times before being lysed.
Lysates were then subjected to a⁄nity chromatography on
m7GTP-Sepharose, which binds eIF4E and associated pro-
teins. The bound material was analysed by SDS^PAGE and
Western blotting. Since this analysis requires very large
amounts of material (approx. 800 Wg, equivalent to 40% of
the cells from one rat heart), it is only possible to study a
limited range of conditions. No detectable 4E-BP1 was asso-
ciated with eIF4E in insulin-treated ARVC, as reported earlier
[12] (Fig. 3). Treatment with CCCP caused an increase in 4E-
BP1 binding by 5 min, but this was only partial, and binding
increased further by 15 and 30 min of treatment. Indeed, a
substantial amount of eIF4G was still clearly associated with
eIF4E at 5 min, although this was lost (due to increased bind-
ing of eIF4E to 4E-BP1) by later times. The increased binding
of 4E-BP1 to eIF4E, which indicates inhibition of mTOR
signalling, occurs later than the much more rapid rise in
eEF2 phosphorylation (Fig. 1). To study earlier times, we
treated ARVC with CCCP for 2 min, a time at which eEF2
pp
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Fig. 2. ATP depletion results in dephosphorylation of S6K1. ARVC were pre-treated with insulin and then with the agents shown (CCCP,
10 WM; oligomycin, 1 WM) for the indicated times. 3, cells treated only with insulin. Equal amounts of cell protein (70 Wg) were analysed by
SDS^PAGE (10% gel, run until the 66-kDa marker was almost at the bottom to maximise resolution) and Western blotting using anti-S6K1
antiserum. Three bands are visible, corresponding to di¡erent phosphorylated forms of the enzyme (as denoted by the labelled arrows). The
starred arrow indicates the least phosphorylated form of S6K1 generated after CCCP or oligomycin treatment.
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phosphorylation is already maximal (Fig. 1). It is clear from
Fig. 3B that there is essentially no e¡ect of CCCP on binding
of 4E-BP1 to eIF4E at this time, indicating that there is no
signi¢cant impairment of signalling via the mTOR pathway.
This is entirely consistent with the data shown in Fig. 2 for
S6K1, which also only underwent signi¢cant dephosphoryla-
tion at relatively late times. The observation that eEF2 phos-
phorylation is already maximally elevated at 1 min after ad-
dition of CCCP, while S6K1 only undergoes phosphorylation
at later times, strongly suggests that the changes in eEF2
phosphorylation are not due to inactivation of mTOR signal-
ling, which can regulate eEF2 in ARVC [12], but rather to
other consequences of ATP depletion. Bolster et al. [29] have
recently reported that injection of AICAR into rats causes
inhibition of mTOR signalling in skeletal muscle. However,
activation of AMPK may also interfere with the synthesis
and/or release of insulin [30,31], making it hard to interpret
these data. The e¡ects on muscle mTOR signalling may, for
example, re£ect changes in circulating insulin levels.
3.4. Conclusions
The data presented here shows that ATP depletion increases
the phosphorylation of eEF2. Like the inhibition of protein
synthesis, this e¡ect is rapid. CCCP has a greater e¡ect on
protein synthesis and on eEF2 phosphorylation than oligomy-
cin. This data suggest that phosphorylation of eEF2 plays an
important role in the inhibition of protein synthesis when
ATP levels fall. eEF2 phosphorylation rises before inhibition
of mTOR signalling is apparent, suggesting that a mechanism
other than changes in mTOR signalling is involved. The ob-
servation that AICAR induces eEF2 phosphorylation points
to a key role for AMPK in these e¡ects. Further work is
required to establish how AMPK regulates eEF2 phosphory-
lation. This mechanism for acutely inhibiting the consumption
of energy by protein synthesis could be of particular impor-
tance in assuring continued supplies of metabolic energy for
contraction and ion pumps in the heart during periods of
relative energy insu⁄ciency.
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Fig. 3. CCCP causes increased binding of the translational repressor
4E-BP1 to eIF4E. A,B: ARVC were treated with insulin and then
with the agents shown (CCCP, 10 WM; AICAR, 1 mM). After lysis,
samples of lysate (750^800 Wg protein) were subjected to a⁄nity
chromatography on m7GTP-Sepharose, which binds eIF4E and pro-
teins associated with it. Bound material was subjected to SDS^
PAGE (12.5% gel) and Western blotting using antisera to eIF4E,
eIF4G or 4E-BP1, as indicated. The signal for eIF4E serves as load-
ing control to which other signals can be normalised. Similar data
were obtained in four separate experiments.
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